Remdesivir
- PMID: 33085408
- Bookshelf ID: NBK563261
Remdesivir
Excerpt
Remdesivir is a broad-spectrum antiviral agent that has showcased its efficacy against a spectrum of viruses, including filoviruses (eg, Ebola, Marburg), coronaviruses (eg, SARS-CoV, MERS-CoV, SARS-CoV-2), paramyxoviruses (eg, parainfluenza type III, Nipah, Hendra, measles, mumps), and Pnemoviridae (eg, respiratory syncytial virus). In vitro studies have demonstrated its antiviral activity against SARS-CoV-2, prompting its consideration as an investigational drug early in the pandemic. Following randomized clinical trials affirming superior clinical efficacy compared to placebo, remdesivir was the first antiviral drug approved by the US Food and Drug Administration (FDA). This approval signifies its role in the clinical management of patients with severe suspected or laboratory-confirmed COVID-19. This activity meticulously explores remdesivir's pharmacology, dosing, indications, contraindications, and potential adverse events to enhance patient outcomes.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5. - PMC - PubMed
-
- Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017 Mar 06;7:43395. - PMC - PubMed
-
- Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396) - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous